Sökning: onr:"swepub:oai:DiVA.org:uu-194865" >
A phase 2a, randomi...
-
Ejskjaer, N.
(författare)
A phase 2a, randomized, double-blind 28-day study of TZP-102 a ghrelin receptor agonist for diabetic gastroparesis
- Artikel/kapitelEngelska2013
Förlag, utgivningsår, omfång ...
-
2012-12-23
-
Wiley,2013
-
printrdacarrier
Nummerbeteckningar
-
LIBRIS-ID:oai:DiVA.org:uu-194865
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-194865URI
-
https://doi.org/10.1111/nmo.12064DOI
Kompletterande språkuppgifter
-
Språk:engelska
-
Sammanfattning på:engelska
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background Gastroparesis causes significant morbidity and treatment options are limited. TZP-102 a novel, macrocyclic, selective, oral ghrelin receptor agonist, was evaluated in a randomized, double-blind, placebo-controlled trial in patients with diabetic gastroparesis. Methods A total of 92 outpatients were randomized to once-daily administrations of 10-mg (n=22), 20-mg (n=21), 40-mg (n=23) TZP-102 or placebo (n=26). The primary endpoint was the change from baseline in gastric half-emptying time (T1/2) utilizing 13C-breath test methodology and secondary endpoints included symptom improvement using patient-reported gastroparesis symptom scores (PAGI-SYM questionnaire) and patient and physician overall treatment evaluations (OTE). Key Results Gastric T1/2 changes were not statistically significant between TZP-102 and placebo after 28days of treatment at any dose. Clinical improvements (-1.0 to -1.4 point mean decrease in symptom severity) occurred in the Gastroparesis Cardinal Symptom Index (GCSI) component of the PAGI-SYM, which was significant vs placebo for all TZP-102 doses combined. Improvements became evident after 1week of treatment. Significantly, more patients given TZP-102 (any dose) had a 50% reduction in baseline GCSI score (28.8%vs 7.7% placebo). Safety profiles were similar across groups. All TZP-102 doses were well-tolerated with no adverse cardiac, weight, or glucose control outcomes. Conclusions & Inferences TZP-102 for 28days, at doses of 10-40mg once daily, was well-tolerated and resulted in a reduction in symptoms of gastroparesis. The lack of correlation between symptom improvement and gastric emptying change is consistent with previous studies in diabetic gastroparesis, and emphasizes the value of patient-defined outcomes in determining therapeutic benefit.
Ämnesord och genrebeteckningar
-
Diabetes type 1
-
Diabetes type 2
-
Diabetic gastroparesis
-
Gastroparesis
-
Oral ghrelin receptor agonist
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Wo, J. M.
(författare)
-
Esfandyari, T.
(författare)
-
Mazen Jamal, M.
(författare)
-
Dimcevski, G.
(författare)
-
Tarnow, L.
(författare)
-
Malik, R. A.
(författare)
-
Hellström, Per M.Uppsala universitet,Gastroenterologi/hepatologi(Swepub:uu)perhe742
(författare)
-
Mondou, E.
(författare)
-
Quinn, J.
(författare)
-
Rousseau, F.
(författare)
-
Mccallum, R. W.
(författare)
-
Uppsala universitetGastroenterologi/hepatologi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:Neurogastroenterology and Motility: Wiley25:2, s. e140-e1501350-19251365-2982
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Ejskjaer, N.
-
Wo, J. M.
-
Esfandyari, T.
-
Mazen Jamal, M.
-
Dimcevski, G.
-
Tarnow, L.
-
visa fler...
-
Malik, R. A.
-
Hellström, Per M ...
-
Mondou, E.
-
Quinn, J.
-
Rousseau, F.
-
Mccallum, R. W.
-
visa färre...
- Artiklar i publikationen
-
Neurogastroenter ...
- Av lärosätet
-
Uppsala universitet